Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Theratechnologies closes US$57.7 million bought deal financing

Fasken
Reading Time 1 minute read

Overview

Client

Theratechnologies

On February 27, 2007, Theratechnologies Inc. announced that it had successfully completed its recently announced public offering of 6,875,000 common shares at a price of $8.40 per share for gross proceeds of $57,750,000. The offering was made through a syndicate of underwriters led by BMO Capital Markets, including Canaccord Capital, National Bank Financial, Desjardins Securities and Jennings Capital. The offering included the 625,000 additional shares issued pursuant to the over-allotment option, which was exercised in full by the underwriters on February 21, 2007. Theratechnologies was advised by a team from Fasken Martineau comprised of Robert Girard, Catherine Isabelle, Teri Hoppenheim, and E. Martin Fisher-Haydis for advice on U.S. matters.

Team